ABCB1-IN-2
ABCB1-IN-2 (compound 16q) is a functional inhibitor that can directly bind to the ABCB1 protein and stabilize its structure without affecting the expression and subcellular localization of ABCB1. ABCB1-IN-2 can increase the sensitivity of MCF-7/ADR cells to paclitaxel (PTX), increase the accumulation of PTX, and prevent the accumulation and excretion of luciferin Rh123 mediated by ABCB1. ABCB1-IN-2, as an ABCB1-mediated multidrug resistance (MDR) reversal agent, shows a strong ability to reverse MDR.
For research use only. We do not sell to patients.
- Formula: C29H29N3O6S
- Molecular Weight:547.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
ABCB1[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
>20 μM
Compound: 16q
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
|
[PMID: 39151276] |
| MCF7 | IC50 |
2.65 nM
Compound: 16q
|
Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM)
Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM)
|
[PMID: 39151276] |
| MCF7 | IC50 |
2.96 nM
Compound: 16q
|
Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM)
Reversal of paclitaxel resistance in human MCF7 cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 2.60 +/- 0.36 nM)
|
[PMID: 39151276] |
| NCI/ADR-RES | IC50 |
>20 μM
Compound: 16q
|
Antiproliferative activity against human MCF7ADR cells incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7ADR cells incubated for 72 hrs by MTT assay
|
[PMID: 39151276] |
| NCI/ADR-RES | IC50 |
0.027 μM
Compound: 16q
|
Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM)
Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 5 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM)
|
[PMID: 39151276] |
| NCI/ADR-RES | IC50 |
10.07 nM
Compound: 16q
|
Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM)
Reversal of paclitaxel resistance in human MCF7ADR cells assessed as reduction in paclitaxel IC50 at 10 uM pretreated with compound for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 6.68 +/- 0.35 microM)
|
[PMID: 39151276] |
Chemical Information
-
Molecular Weight 547.62
-
Formula C29H29N3O6S
-
SMILES
COC1=C(OC)C(OC)=CC(C2=C(C3=CC(OC)=C(OC)C(OC)=C3)C(C)=NC4=CC(C5=CC=CS5)=NN24)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz